Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bullinger

Showing results (191-200 of 385) with videos related to

Pageof 39
Sort By:
The Journal of Pathology. Clinical Research|November 12, 2020
TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanismsMaren Schmiester, Anna Dolnik, Uwe Kornak, et al.
Oncotarget|August 31, 2013
CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemiaAudrey Astori, Hanne Fredly, Thomas Aquinas Aloysius, et al.
Leukemia|October 3, 2019
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)Tatjana Meyer, Nikolaus Jahn, Stefanie Lindner, et al.
Journal for Immunotherapy of Cancer|March 21, 2025
Leucine-rich α-2 glycoprotein 1 (LRG1) during inflammatory complications after allogeneic stem cell transplantation and CAR-T cell therapySarah Mertlitz, Katarina Riesner, Martina Kalupa, et al.
Leukemia & Lymphoma|August 20, 2021
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signalsSophy Denker, Aitomi Bittner, Mareike Frick, et al.
Oncology Letters|September 27, 2024
Increased abundance of <i>Firmicutes</i> and depletion of <i>Bacteroidota</i> predicts poor outcome in chronic lymphocytic leukemiaMagdalena Paziewska, Monika Szelest, Michał Kiełbus, et al.
Nature Communications|February 24, 2022
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myelomaYuen Lam Dora Ng, Evelyn Ramberger, Stephan R Bohl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterizationFrank G Rücker, Lars Bullinger, Carsten Schwaenen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study groupVerena I Gaidzik, Peter Paschka, Daniela Späth, et al.
Oncotarget|December 10, 2017
<i>Protein phosphatase 4 regulatory subunit 2 (PPP4R2)</i> is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repairJulia K Herzig, Lars Bullinger, Alpaslan Tasdogan, et al.
Pageof 39

Showing results (191-200 of 385) with videos related to

Sort By:
Pageof 39
The Journal of Pathology. Clinical Research|November 12, 2020
TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanismsMaren Schmiester, Anna Dolnik, Uwe Kornak, et al.
Oncotarget|August 31, 2013
CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemiaAudrey Astori, Hanne Fredly, Thomas Aquinas Aloysius, et al.
Leukemia|October 3, 2019
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)Tatjana Meyer, Nikolaus Jahn, Stefanie Lindner, et al.
Journal for Immunotherapy of Cancer|March 21, 2025
Leucine-rich α-2 glycoprotein 1 (LRG1) during inflammatory complications after allogeneic stem cell transplantation and CAR-T cell therapySarah Mertlitz, Katarina Riesner, Martina Kalupa, et al.
Leukemia & Lymphoma|August 20, 2021
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signalsSophy Denker, Aitomi Bittner, Mareike Frick, et al.
Oncology Letters|September 27, 2024
Increased abundance of <i>Firmicutes</i> and depletion of <i>Bacteroidota</i> predicts poor outcome in chronic lymphocytic leukemiaMagdalena Paziewska, Monika Szelest, Michał Kiełbus, et al.
Nature Communications|February 24, 2022
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myelomaYuen Lam Dora Ng, Evelyn Ramberger, Stephan R Bohl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterizationFrank G Rücker, Lars Bullinger, Carsten Schwaenen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study groupVerena I Gaidzik, Peter Paschka, Daniela Späth, et al.
Oncotarget|December 10, 2017
<i>Protein phosphatase 4 regulatory subunit 2 (PPP4R2)</i> is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repairJulia K Herzig, Lars Bullinger, Alpaslan Tasdogan, et al.
Pageof 39